The Association Between Vitamin D and Acute Rejection in Human Kidney Transplantation: A Systematic Review and Meta-analysis Study

Mohammad Mirzakhani  
Babol University of Medical Sciences  
https://orcid.org/0000-0002-8831-3006

Sheyda Mohammadkhani  
Babol University of Medical Sciences

Shirin Hekmatirad  
Babol University of Medical Sciences

Soudabeh Aghapour  
Babol University of Medical Sciences

Negar Gorjizadeh  
Department of Cell and Molecular Biology, Faculty Biological Sciences, Kharazmi University, Tehran, Iran

Mehdi Shahbazi  
Babol University of Medical Sciences

Mousa Mohammadnia-Afrouzi  
m.mohammadnia@mubabol.ac.ir  
Babol University of Medical Sciences  
https://orcid.org/0000-0003-2083-7425

Systematic Review

Keywords: kidney transplantation, vitamin D, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, acute rejection, inflammation

DOI: https://doi.org/10.21203/rs.3.rs-133926/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Background:** Vitamin D (VitD) deficiency is associated with several diseases such as multiple sclerosis, rheumatoid arthritis, respiratory infection, and so forth. In the field of transplantation (kidney transplantation), some studies reported that patients with VitD deficiency are of increased risk of acute rejection, but other studies did not show such a risk. On the other hand, since VitD is a modulatory factor and can reduce the inflammatory response, understanding the exact role of it in transplantation may contribute to tolerance condition in these patients.

**Methods:** The electronic databases, including PubMed, Scopus, Embase, ProQuest, Web of Science, and Google Scholar, were searched for eligible studies. In general, 14 studies with a total of 4,770 patients were included in this meta-analysis. Regarding the methodological heterogeneity, we selected a random-effects combination model. Moreover, OR was chosen as an effect size for this study.

**Results:** After the combination of 14 studies, we showed that patients in the VitD-deficient group had an 82% increased risk of acute rejection compared with patients in the VitD-sufficient group, and this effect was significant (OR 1.82; 95% confidence interval [CI] [1.29, 2.56]; \( I^2 = 52.3\% \)). This result was significant, and, regarding the narrow CI, it can be a conclusive result. Study quality and gender variables were the main sources of inconsistent results in the primary studies. Moreover, using meta-regression, we showed that VitD deficiency (independent from the estimated glomerular filtration rate (eGFR) of patients) increased the risk of acute rejection.

**Conclusion:** The normal VitD status of patients a few days before and after transplantation can reduce the risk of acute rejection, as it has definite modulatory effects on immune cells.

1. Introduction

Vitamin D (VitD) is a fat-soluble steroid, which participates in bone health through regulating the calcium and phosphate metabolism. VitD is produced after skin exposure to ultraviolet solar irradiation or can be acquired in the diet or vitamin supplements. Cholecalciferol (D3) and ergocalciferol (D2) are two main sources of VitD, which needs two steps of hydroxylation to become biologically active. After the first hydroxylation, which is performed in the liver, the D2 and D3 are converted to 25-hydroxyvitamin D. It is the main type of VitD in the circulation with a half-life of 2–3 weeks and is routinely measured to determine the VitD status. The second hydroxylation is performed in the kidney through cytochrome P450 1-α hydroxylase enzyme CYP27B1, leading to the production of the active form of VitD, i.e., 1,25-dihydroxyvitamin D (1-4).

VitD is a crucial factor for the immune system, as its receptor is expressed on monocytes, macrophages, dendritic cells (DCs), and activated lymphocytes. 25-hydroxyvitamin D can bind to its receptor on mentioned immune cells and be converted to 1,25-dihydroxyvitamin D. Then, 1,25-dihydroxyvitamin D increases the production of antimicrobial peptides, such as cathelicidin and defensin (3, 5-7).

In contrast, the effect of VitD on DCs and T/B lymphocytes is regulatory. DCs and T/B lymphocytes are the major immune cells, initiating the immune responses of the recipient against the allograft (3). The VitD reduces the inflammatory cytokines of T helper 1 (TH1) and TH17 and increases the anti-inflammatory cytokines of TH2 and regulatory T cells (Tregs). Moreover, VitD reduces the proliferation, immunoglobulin G (IgG), and immunoglobulin M (IgM) of B lymphocytes (3, 6, 8-11). Another important regulatory effect of VitD is on DCs. DCs are very crucial cells to initiate and stimulate T cells against the allograft. VitD could reduce the antigen presentation capacity of DCs by reducing the major histocompatibility class II (MHCII) and co-stimulatory molecules. These regulatory effects of VitD on the immune system may contribute to a better function of allograft and reduce the risk of allograft rejection (3, 12, 13).

VitD deficiency (VitD < 20 ng/ml) (14) is associated with several immune and non-immune diseases and disorders, including multiple sclerosis, rheumatoid arthritis, respiratory infection (3), cystic fibrosis (15), cardiovascular (16), and hematological diseases (17). Moreover, in the field of transplantation (kidney transplantation), some studies reported that VitD deficiency remarkably increases the risk of acute rejection (18, 19), while others did not indicate such a risk (20, 21). Since VitD deficiency is more common in the kidney transplant recipients compared with the general population (19, 22), and there is no consistency regarding the association between VitD concentrations and acute rejection, we aimed to carry out the first systematic review and meta-analysis to clarify whether VitD-deficient patients are more susceptible to acute rejection.

2. Methods

2.1. Protocol and Registration

This systematic review and meta-analysis study was prospectively registered with the National Institute for Health Research (PROSPERO: CRD42020216086). We followed the Reporting Checklist for Meta-analyses of Observational Studies (MOOSE) (23) and Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) (24) statements to report this study.

2.2. Eligibility Criteria

2.2.1. Type of Study
All observational studies (such as cross-sectional, case-control, and cohort), as well as interventional studies (randomized or non-randomized), were included in this study. In contrast, case-report, case-series, narrative reviews, animal studies, and letters were excluded.

2.2.2. Type of Participants

Kidney transplant recipients with and without acute rejection were enrolled in this study, which their pre- or post-transplant 25-hydroxyvitamin D levels were assessed. Recipients features are as follows: (i) biopsy-proven or clinically suspected acute rejection, (ii) received living or deceased donor kidney transplant, (iii) received their transplant for the first time or more, (iv) have experienced acute rejection up to 12 months after transplantation, and (v) with any age and gender. We excluded studies that did not separate the acute and chronic rejected patients and that measured 1,25-dihydroxyvitamin D instead of 25-hydroxyvitamin D.

2.2.3. Outcome

The outcome is the occurrence of acute rejection in kidney transplant recipients. Acute rejection is any type of cell-mediated or antibody-mediated rejection with any score or grade.

2.3. Search Strategy

The electronic databases searched by authors were PubMed, Scopus, Embase, ProQuest, Web of Science, and Google Scholar. Moreover, the gray literature (conferences/congress papers and theses) and reference lists of included studies were searched. The primary studies are from 1 January 1990 up to 31 October 2020. We used the keywords “kidney transplantation,” “acute rejection,” “25-hydroxyvitamin D,” and their synonym for the search syntax. The Medical Subject Headings (MeSH) and free-text method were used to create search syntax. The search syntax of the PubMed database is shown in Supplemental File 1.

2.4. Study Selection

The records searched in all databases were exported to the EndNote software, and duplicated records were removed. Authors performed the screening process using titles and abstracts. Then, two reviewers independently read the full text of screened papers and selected those that had the main data for conducting meta-analysis. Any disagreement was resolved by consensus.

2.5 Risk of Bias Assessment

The quality assessment of included studies was independently done by two reviewers using the Newcastle-Ottawa Quality Assessment Scale (NOS) for observational studies (25). Moreover, the quality of a trial study was assessed using the Cochrane checklist (26). The modified version of NOS checklists for observational studies are shown in Supplemental File 2.

2.6. Data Extraction

Two reviewers independently extracted data from included studies using a data extraction form as follows: first author name, publication year, maintenance therapy, induction therapy (IT), donor type (living vs. deceased), estimated glomerular filtration rate (eGFR), and age and gender of study subjects. Any disagreement was resolved by consensus, and, for incomplete data, we contacted the corresponding authors of the studies.

2.7. Data Synthesis and Analyses

The main data for conducting the meta-analysis are as follows (i.e., four numbers): the numbers of non-acute and acute rejection patients in the VitD-deficient (VitD < 20 ng/ml) group and the numbers of non-acute and acute rejection patients in the VitD-sufficient (VitD ≥ 20 ng/ml) group. We used the term "sufficient" for VitD ≥ 20 ng/ml patients in the whole manuscript and figures. According to the type of included studies and main data for performing the meta-analysis, we employed OR as an effect size to be reported in this study. According to the methodological heterogeneity between included studies, we selected a random-effects model as an appropriate combination model (27). The pooled effect size was plotted using a forest plot.

Statistical heterogeneity between included studies was evaluated using the $I^2$ index (28). The severe statistical heterogeneity was considered $I^2 > 50%$.

2.8. Publication Bias Assessment

We used three methods to assess publication bias as follows: the funnel plot (which is the visual assessment of publication bias), Begg's (29) and Egger's (30) tests (which statistically assess publication bias), and trim and fill method (which assesses probable missing papers) (31).

2.9. Additional Analyses

2.9.1. Subgroup Analyses

We performed some subgroup analyses to find out potential sources of statistical heterogeneity observed between included studies. The other purpose of subgroup analyses was to know whether the pooled effect size was influenced by different variables in each subgroup analysis.
Subgroup analyses were performed as follows:

**Quality of Studies**

Studies with high quality (i.e., $\geq 6$) were compared with those with low quality (i.e., < 6).

**Induction Therapy**

Studies with induction therapy (IT) were compared with those without IT.

**Age**

Studies with patients $\leq 47$ years were compared with those with patients $> 47$ years in each group (VitD < 20 ng/ml and VitD $\geq 20$ ng/ml) separately.

**Gender**

Studies with more male patients were compared with those with fewer male patients.

**Donor Type**

Studies with living donor more than 50% were compared with those with living donor less than 50% in each group (VitD < 20 ng/ml and VitD $\geq 20$ ng/ml) separately.

### 2.9.2 Meta-Regression Analysis

Regarding the low number of studies that reported the eGFR of their patients, we decided to do meta-regression to evaluate whether eGFR affect the pooled effect size.

### 2.9.3 Sensitivity Analysis

We utilized the one-out-remove method to do sensitivity analysis. In this method, the pooled effect size was recalculated after removing the effect of each study. This method was used to know whether there was any difference between the results after removing a study. If yes, how much does the recalculated pooled effect size change?

This study was analyzed using STATA Version 13 (StataCorp, College Station, TX, USA).

### 3. Results

#### 3.1 Study Selection

After searching the electronic databases, we identified a total of 9,398 records. Literature search procedure is shown in Figure 1. After screening the records according to the title and abstract, 924 records remained, and, after removing duplicated records, 766 records remained. After full-text assessment of 766 records, 14 records included in the meta-analysis. Finally, we included 14 studies (18-22, 32-40) with a total of 4,770 kidney transplant recipients in this systematic review and meta-analysis.

#### 3.2 Study Characteristics

Studies included in this meta-analysis are from 2005 to 2020. Among 14 included studies, 10 studies were cohort studies, three were cross-sectional, and one was a randomized clinical trial (RCT). Eleven studies reported the patients’ characteristics in two groups (i.e., VitD-deficient and -sufficient groups), while three studies did not. These studies reported several variables including immunosuppressive agents (14 studies), age (11 studies), gender (11 studies), donor type (10 studies), and eGFR (nine studies) (see Table 1). Moreover, the quality of all 14 included studies is reported in Supplemental File 3.

#### 3.3 The Association Between VitD Deficiency and Acute Rejection

Patients in the VitD-deficient group had an 1.82-fold increased risk of acute rejection (82%) compared with patients in the VitD-sufficient group, and this effect was significant ($OR=1.82; 95\%$ confidence interval [CI] [1.29, 2.56]; $I^2 = 52.3\%$). CI was narrow, which indicated that this result was conclusive and can be generalized to a larger population (Figure 2).

#### 3.3.1 Publication Bias Assessment

For the publication bias assessment, three methods were employed. As a first method, the funnel plot showed a homogeneous pattern and therefore non-considerable publication bias (Supplemental Figure 1). As a second method, in line with the previous method, Begg's and egger's tests showed...
non-considerable publication bias as well ($p = 0.913$ and $p = 0.744$, respectively). Egger’s graph is shown in Supplemental Figure 2. Finally, as a third method, the trim and fill method added one paper to our studies; however, the added study did not affect the pooled effect size (Figure 3 and Supplemental File 4).

3.3.2. Subgroup Analyses

As it was shown in Figure 1, primary studies had different results. We performed some subgroup analyses to find potential sources of this statistical heterogeneity. Moreover, subgroup analyses let us analyze studies that are similar together on the aspect of at least one variable. The results of subgroup analyses are summarized in Table 2.

**Quality of Studies**

High-quality studies were compared with low-quality ones. There were six studies in the high-quality subgroup and eight studies in the low-quality one. High-quality studies showed 2.16-fold increased risk of acute rejection. The results of both high-quality ($OR = 2.16; 95\% CI [1.21, 3.87]; I^2 = 69.5\%$) and low-quality subgroups ($OR = 1.41; 95\% CI [1.04, 1.90]; I^2 = 0.0\%$) were significant and consistent with the overall result (Figure 4).

**Induction Therapy**

There were seven studies in each subgroup. The results of both IT ($OR = 1.78; 95\% CI [1.00, 3.16]; I^2 = 62.7\%$) and non-IT subgroups ($OR = 1.82; 95\% CI [1.17, 2.84]; I^2 = 36.7\%$) were consistent with the overall result. The result in the IT subgroup was not significant (Supplemental Figure 3). This subgroup did not affect the pooled effect size.

**Age: In the Deficient and Sufficient Groups**

Among 14 studies, 11 studies had age information of both deficient and sufficient groups separately. VitD-deficient patients ≤ 47 years showed a 2.23-fold increased risk of acute rejection ($OR = 2.23; 95\% CI [1.28, 3.86]; I^2 = 27.7\%$, which was significant. VitD-deficient patients > 47 years showed a 1.61-fold increased risk of acute rejection (61%) ($OR = 1.61; 95\% CI [0.92, 2.83]; I^2 = 44.1\%$, which was not significant (Figure 5).

VitD-sufficient patients ≤ 47 years showed a 2.40-fold increased risk of acute rejection, which was not significant ($OR = 2.40; 95\% CI [1.00, 5.78]; I^2 = 37.2\%$). VitD-sufficient patients > 47 years showed a 1.75-fold increased risk of acute rejection (75%), which was significant ($OR = 1.75; 95\% CI [1.04, 2.96]; I^2 = 64.3\%$) (Supplemental Figure 4).

**Gender**

Among 14 studies, 11 studies had gender information of both deficient and sufficient groups separately. Studies with more male patients showed a 2.85-fold increased risk of acute rejection, which was significant ($OR = 2.85; 95\% CI [1.31, 6.18]; I^2 = 12.7\%$). Studies with fewer male patients showed a 1.65-fold increased risk of acute rejection (65%), which was not significant ($OR = 1.65; 95\% CI [0.97, 2.79]; I^2 = 66.7\%$) (Figure 6).

Moreover, studies with more male patients in the VitD-deficient group showed a 2.58-fold increased risk of acute rejection, which was significant ($OR = 2.58; 95\% CI [1.94, 3.43]; I^2 = 0.0\%$). Studies with fewer male patients in the VitD-deficient group showed a 1.68-fold increased risk of acute rejection (68%), which was not significant ($OR = 1.68; 95\% CI [0.91, 3.09]; I^2 = 52.3\%$) (Supplemental Figure 5).

Studies with more male patients in the VitD-sufficient group showed a 3.20-fold increased risk of acute rejection, which was significant ($OR = 3.20; 95\% CI [1.56, 6.56]; I^2 = 5.0\%$). Studies with fewer male patients in the VitD-sufficient group showed a 1.58-fold increased risk of acute rejection (58%), which was not significant ($OR = 1.58; 95\% CI [0.94, 2.65]; I^2 = 65.2\%$) (Supplemental Figure 6).

**Donor Type**

Among 14 studies, 10 studies had donor type information. Studies with both living and deceased donors showed a 1.79-fold increased risk of acute rejection (79%), which was significant ($OR = 1.79; 95\% CI [1.12, 2.87]; I^2 = 57.7\%$). Studies with living donors showed a 3.60-fold increased risk of acute rejection ($OR = 3.60; 95\% CI [0.81, 16.11]; I^2 = 60.4\%$). However, this result was not significant and conclusive. (Supplemental Figure 7).

**Meta-Regression Analysis**

Nine studies reported the rate of eGFR. We performed a meta-regression analysis on eGFR in each group separately. The eGFR of patients did not affect the pooled effect size. In other words, VitD deficiency independent from the eGFR of patients increased the risk of acute rejection (Figure 7).

**Sensitivity Analysis**

Sensitivity analysis showed that if the studies are separately omitted, the pooled effect size does not change remarkably. Therefore, the pooled effect size had a robust result (Figure 8 and Supplemental File 5).
4. Discussion

A total of 14 studies with 4,770 kidney transplant recipients were eligible to be included in this study. This is the first systematic review and meta-analysis study, which assesses the association between VitD concentration and the risk of acute rejection in kidney transplant recipients. The results of primary studies regarding the association between VitD and the risk of acute rejection were not conclusive. Some of them indicated that VitD deficiency is associated with acute rejection occurrence, but others not. These different statistical results may result from the distinct characteristics of studies’ subjects. Thus, we performed different subgroup analyses to find the potential sources of statistical heterogeneity observed between primary studies.

In general, after the combination of all studies (14 studies and 4,770 patients), we showed that patients with VitD deficiency had an 82% increased risk of acute rejection. This result was not influenced by random errors, and, regarding the narrow CI, we can conclude that this result is conclusive and can be generalized to a larger population. Further, we indicated that several variables separately reduced the statistical heterogeneity (Table 2). For instance, study quality and gender of patients were the most important factors that reduced the heterogeneity. As an example, in the low-quality category, the heterogeneity was reduced from 52.3% to 0.0%; further, in studies with more male patients, the heterogeneity was reduced from 52.3% to 0.0% and 5.0% in the deficient and sufficient groups, respectively.

The study quality and male gender also affected the pooled effect size. High-quality studies increased the risk of acute rejection from OR 1.82 to OR 2.91, while low-quality studies reduced the risk of acute rejection from OR 1.82 to OR 1.41. In other words, the association between VitD and the risk of acute rejection is higher in high-quality studies compared with low-quality ones. Thus, according to high quality studies, VitD-deficient patients had a 2.9-fold increased risk of acute rejection, which was a significant and conclusive result.

As mentioned above, another factor that affected the pooled effect size was the male gender. Studies with more male patients increased the pooled effect size from OR 1.82 to OR 2.85, which, regarding the CI, this result is inconclusive. On the other hand, studies with fewer male patients reduced it from OR 1.82 to OR 1.65.

Similar results were observed when VitD-deficient or -sufficient groups had more male patients (Table 2). The result of more-male-patients subgroup in the deficient group was significant and partially conclusive. However, the result of more-male-patients subgroup in the sufficient group was inconclusive. Consequently, it could be implied that male patients with VitD deficiency are more susceptible to acute rejection compared with female patients with VitD deficiency.

The age of patients was another factor that affected the pooled effect size. Patients with VitD deficiency ≤ 47 years showed a 2.23-fold increased risk of acute rejection, which was significant and partially conclusive. Consequently, besides the male gender variable, patients with VitD deficiency ≤ 47 years are more susceptible to acute rejection compared with patients with VitD deficiency > 47 years.

Using meta-regression, we assessed the effect of eGFR on the pooled effect size. This analysis showed that patients with VitD deficiency independent from their eGFR had an increased risk of acute rejection.

After transplantation, the inflammatory reactions are initiated against the allograft. Because of danger signals and innate allore cognition, innate immunity is immediately activated against the allograft and thereby result in the activation of adaptive immunity. These inflammatory responses have a negative effect on the transplantation outcome and could be a reason for acute rejection (41-46). Given the anti-inflammatory role of VitD (which was stated in the Introduction section), VitD non-deficiency (≥ 20 ng/ml) may modulate such inflammation and reduce the risk of acute rejection.

In summary, the result of this systematic review and meta-analysis study indicated that patients with VitD deficiency had an increased risk of acute rejection. In addition, study quality and male gender were the main sources of statistical heterogeneity observed in the primary studies. Regarding the modulatory effect of VitD and also its role in reducing the risk of acute rejection, we suggest that clinicians keep the VitD status of their patients normal, before and after transplantation.

Declarations

Ethical Approval and Consent to participate
Not applicable

Consent for publication
Not applicable

Availability of data and material
The datasets analyzed in this article are not publicly available. Requests to access the datasets should be directed to the Mousa Mohammadnia-Afrouzi (m.mohammadnia@mubabol.ac.ir).

Conflict interest statement
The authors declare no conflict of interest.

Funding

Not applicable

Authors' contributions

M.M created a search syntax, wrote the manuscript, performed meta-analysis, and screening processes. S.M performed screening and selection processes. S.H performed screening and selection processes. S.A performed screening and data extraction processes. N.G performed screening and data extraction processes. M.S wrote the manuscript and performed quality analysis processes. M.MA wrote the manuscript, performed quality analysis processes, and reviewed the final version of the manuscript.

Acknowledgments

Not applicable

References

<table>
<thead>
<tr>
<th>ID</th>
<th>Author</th>
<th>Study type</th>
<th>Study quality</th>
<th>Immunosuppressive agents</th>
<th>Age(^1)</th>
<th>Age(^2)</th>
<th>Gender(^1)</th>
<th>Gender(^2)</th>
<th>Donor type</th>
<th>eGFR(^1)</th>
<th>eGFR(^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Park et al.</td>
<td>Cohort</td>
<td>High</td>
<td>Triple therapy plus IT</td>
<td>≤ 47</td>
<td>&gt; 47</td>
<td>With more male patients</td>
<td>With more male patients</td>
<td>Both living and deceased donors</td>
<td>63 ml/min/1.73 m(^2)</td>
<td>60 ml/min/1.73 m(^2)</td>
</tr>
<tr>
<td>2</td>
<td>Kulshrestha et al. (2013)</td>
<td>Cohort</td>
<td>Low</td>
<td>Triple therapy</td>
<td>&gt; 47</td>
<td>≤ 47</td>
<td>With more male patients</td>
<td>With fewer male patients</td>
<td>Both living and deceased donors</td>
<td>54 ml/min/1.73 m(^2)</td>
<td>57 ml/min/1.73 m(^2)</td>
</tr>
<tr>
<td>3</td>
<td>Lee et al.</td>
<td>Cohort</td>
<td>High</td>
<td>Triple therapy plus IT</td>
<td>&gt; 47</td>
<td>&gt; 47</td>
<td>With fewer male patients</td>
<td>With more male patients</td>
<td>Both living and deceased donors</td>
<td>40 ml/min/1.73 m(^2)</td>
<td>39 ml/min/1.73 m(^2)</td>
</tr>
<tr>
<td>4</td>
<td>Mehrotra et al. (2018)</td>
<td>Cohort</td>
<td>Low</td>
<td>Triple therapy plus IT</td>
<td>≤ 47</td>
<td>≤ 47</td>
<td>With more male patients</td>
<td>With more male patients</td>
<td>Living donors</td>
<td>69 ml/min/1.73 m(^2)</td>
<td>86 ml/min/1.73 m(^2)</td>
</tr>
<tr>
<td>5</td>
<td>Ma et al.</td>
<td>Cross-section</td>
<td>High</td>
<td>Triple therapy</td>
<td>&gt; 47</td>
<td>&gt; 47</td>
<td>With fewer male patients</td>
<td>With fewer male patients</td>
<td>Both living and deceased donors</td>
<td>54 ml/min/1.73 m(^2)</td>
<td>58 ml/min/1.73 m(^2)</td>
</tr>
<tr>
<td>6</td>
<td>Gregorini et al. (2017)</td>
<td>Cohort</td>
<td>Low</td>
<td>Triple therapy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>51 ml/min/1.73 m(^2)</td>
<td>49 ml/min/1.73 m(^2)</td>
</tr>
<tr>
<td>7</td>
<td>Kim et al.</td>
<td>Cohort</td>
<td>High</td>
<td>Triple therapy</td>
<td>≤ 47</td>
<td>≤ 47</td>
<td>With fewer male patients</td>
<td>With more male patients</td>
<td>Living donors</td>
<td>58 ml/min/1.73 m(^2)</td>
<td>61 ml/min/1.73 m(^2)</td>
</tr>
<tr>
<td>8</td>
<td>Lee et al.</td>
<td>Cross-section</td>
<td>Low</td>
<td>Triple therapy</td>
<td>≤ 47</td>
<td>&gt; 47</td>
<td>With fewer male patients</td>
<td>With fewer male patients</td>
<td>Living donors</td>
<td>54 ml/min/1.73 m(^2)</td>
<td>57 ml/min/1.73 m(^2)</td>
</tr>
<tr>
<td>9</td>
<td>Bienaimé et al. (2013)</td>
<td>Cohort</td>
<td>High</td>
<td>Triple therapy plus IT</td>
<td>&gt; 47</td>
<td>&gt; 47</td>
<td>With fewer male patients</td>
<td>With more male patients</td>
<td>Both living and deceased donors</td>
<td>57 ml/min/1.73 m(^2)</td>
<td>58 ml/min/1.73 m(^2)</td>
</tr>
<tr>
<td>10</td>
<td>Astor et al.</td>
<td>Cohort</td>
<td>High</td>
<td>Triple therapy plus IT</td>
<td>≤ 47</td>
<td>&gt; 47</td>
<td>With more male patients</td>
<td>With fewer male patients</td>
<td>Both living and deceased donors</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>11</td>
<td>Torres et al.</td>
<td>Cross-section</td>
<td>Low</td>
<td>Triple therapy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>12</td>
<td>Wissing et al. (2005)</td>
<td>RCT</td>
<td>Low</td>
<td>Triple therapy plus IT</td>
<td>≤ 47</td>
<td>≤ 47</td>
<td>With fewer male patients</td>
<td>With more male patients</td>
<td>Both living and deceased donors</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>13</td>
<td>Mehrotra et al. (2020)</td>
<td>Cohort</td>
<td>Low</td>
<td>Triple therapy plus IT</td>
<td>≤ 47</td>
<td>≤ 47</td>
<td>With more male patients</td>
<td>With more male patients</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>14</td>
<td>Obi et al.</td>
<td>Cohort</td>
<td>Low</td>
<td>Triple therapy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 1. Characteristics of 14 included studies.

Note. eGFR: estimated glomerular filtration rate; IT: induction therapy; RCT: randomized clinical trail
1 in the VitD deficient group
2 in the VitD sufficient group

Table 2. The results of all subgroup analyses compared with total result.

<table>
<thead>
<tr>
<th>Subgroup variable</th>
<th>Category</th>
<th>Number of studies</th>
<th>Pooled effect size</th>
<th>95% CI</th>
<th>( \eta^2 )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study quality</td>
<td>High</td>
<td>6</td>
<td>2.16</td>
<td>1.21, 3.87</td>
<td>69.5%</td>
</tr>
<tr>
<td></td>
<td>Low</td>
<td>8</td>
<td>1.41</td>
<td>1.04, 1.90</td>
<td>0.0%</td>
</tr>
<tr>
<td>Induction therapy</td>
<td>IT</td>
<td>7</td>
<td>1.78</td>
<td>1.00, 3.16</td>
<td>62.7%</td>
</tr>
<tr>
<td></td>
<td>non-IT</td>
<td>7</td>
<td>1.82</td>
<td>1.17, 2.84</td>
<td>36.7%</td>
</tr>
<tr>
<td>Age in the deficient group</td>
<td>( \leq 47 ) years</td>
<td>7</td>
<td>2.23</td>
<td>1.28, 3.86</td>
<td>27.7%</td>
</tr>
<tr>
<td></td>
<td>&gt; 47 years</td>
<td>4</td>
<td>1.61</td>
<td>0.92, 2.83</td>
<td>44.1%</td>
</tr>
<tr>
<td>Age in the sufficient group</td>
<td>&gt; 47 years</td>
<td>6</td>
<td>1.75</td>
<td>1.04, 2.96</td>
<td>64.3%</td>
</tr>
<tr>
<td></td>
<td>( \leq 47 ) years</td>
<td>5</td>
<td>2.40</td>
<td>1.00, 5.78</td>
<td>37.2%</td>
</tr>
<tr>
<td>Gender</td>
<td>With more male patients</td>
<td>5</td>
<td>2.85</td>
<td>1.31, 6.18</td>
<td>12.7%</td>
</tr>
<tr>
<td></td>
<td>With fewer male patients</td>
<td>6</td>
<td>1.65</td>
<td>0.97, 2.79</td>
<td>66.7%</td>
</tr>
<tr>
<td>Gender in the deficient group</td>
<td>With more male patients</td>
<td>5</td>
<td>2.58</td>
<td>1.94, 3.43</td>
<td>0.0%</td>
</tr>
<tr>
<td></td>
<td>With fewer male patients</td>
<td>6</td>
<td>1.68</td>
<td>0.91, 3.09</td>
<td>52.3%</td>
</tr>
<tr>
<td>Gender in the sufficient group</td>
<td>With more male patients</td>
<td>5</td>
<td>3.20</td>
<td>1.56, 5.56</td>
<td>5.0%</td>
</tr>
<tr>
<td></td>
<td>With fewer male patients</td>
<td>6</td>
<td>1.58</td>
<td>0.94, 2.65</td>
<td>65.2%</td>
</tr>
<tr>
<td>Donor type in the deficient group</td>
<td>Both deceased and living donors</td>
<td>7</td>
<td>1.79</td>
<td>1.12, 2.87</td>
<td>57.7%</td>
</tr>
<tr>
<td></td>
<td>living donor</td>
<td>3</td>
<td>3.60</td>
<td>0.81, 16.11</td>
<td>60.4%</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>14</td>
<td>1.82</td>
<td>1.29, 2.56</td>
<td>52.3%</td>
</tr>
</tbody>
</table>